BioPharmSignal logoBioPharmSignal

Biotech News

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

AngioDynamics (ANGO)AngioDynamicsCompany update

Policy Applies Medical Necessity Criteria Across Medicare Administrative Contractor (MAC) Jurisdictions for Eligible Prostate and Liver Cancer Patients LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 14, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused

Related news

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

IDYAIDEAYA Biosciences2026-10-19 10:00 EST

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

IARTIntegra LifeSciences2026-10-02 12:05 EST

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

IARTIntegra LifeSciences2026-09-25 13:05 EST

Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026

View all latest news

AngioDynamics

Vascular and Interventional Technology AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business. Mechanical Thrombectomy AlphaVac and AngioVac are mechanical aspiration...

Recent company news

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

ANGOAngioDynamics2026-10-14 11:00 EST

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGOAngioDynamics2026-10-08 10:00 EST

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

ANGOAngioDynamics2026-10-02 10:00 EST

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

Stock data

Close
11.89 USD
Market cap
453.68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States